Manila Times Business
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
BEIJING and BRIDGEWATER, N.J., June 12, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter "Gan & Lee", stockcode: 603087.SH) announced that two of its core pipeline products in the fields of diabetes and obesity treatment have recently achieved positive clinical results.SUPER-3: Insulin Ludefen (GZR4)combined with insulin aspart demonstrated superior HbA1c reduction in adults previously treated with basal-bolus insulin or premixed/dual insulin analogs. Insulin Ludefen is an investigati
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
Just now
What Is XM Partner Code Y8MH4 and Why Is It Growing?
Just now
Eight Saints Launches Firm Intentions, a Clean Anti-Aging Neck Cream, Targeting Skincare's Most Overlooked Area
Just now
Limitless Sky Launches empty-legs-flights.com - The World’s Most Comprehensive Real-Time Empty Leg Private Jet Platform
Just now